Physician profile
Chadi Obeid
NPI 1346470226
$1,486.28
in general payments reported to CMS, 2019-2025
14 companies · $95.88 in 2025
The $95.88 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.45 · 2020: $251 · 2021: $605 · 2022: $200 · 2023: $154 · 2024: $80.97 · 2025: $95.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $173 · Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $172.95 |
| Food and Beverage | $157.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $294.91 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $290.63 | 2019-2023 | |
| Daiichi Sankyo INC. | $158.90 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $146.00 | 2021-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $135.48 | 2021-2023 | |
| Akebia Therapeutics INC | $98.06 | 2021-2022 | |
| Travere Therapeutics, INC. | $75.34 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $73.09 | 2019-2024 | Velphoro |
| Horizon Therapeutics Plc | $70.85 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.50 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $27.20 | 2023 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $22.05 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Glaxosmithkline, LLC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadi Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.